Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

1,074.83 -3.81 (-0.35%)
Streaming Delayed Price Updated: 2:31 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 187,127
Open 1,073.62
Bid (Size) 1,073.78 (4)
Ask (Size) 1,075.86 (2)
Prev. Close 1,078.63
Today's Range 1,073.40 - 1,085.00
52wk Range 726.12 - 1,106.16
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth. 
Via Benzinga
3 Standout Stocks to Buy for the Next Bull Market
These standout stocks to buy for a bull market offer promising potential for significant gains as market conditions continue to strengthen. 
Via InvestorPlace

Performance

YTD
+18.77%
+18.77%
1 Month
+2.26%
+2.26%
3 Month
+20.43%
+20.43%
6 Month
+12.45%
+12.45%
1 Year
+44.87%
+44.87%

More News

Read More
Stocks to Buy: 7 Founder-Led Companies Set to Outperform
Via InvestorPlace
CPI Data Sparks Rally in Biotech Stocks
Via MarketBeat
Topics ETFs Economy
Exposures Interest Rates
The Analyst Landscape: 14 Takes On Regeneron Pharmaceuticals
Via Benzinga
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $3,300 Today
Via Benzinga
Looking Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Via Benzinga
Topics Economy
Exposures Interest Rates
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
Via The Motley Fool
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Via Benzinga
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
Via Benzinga
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Moderna, Regeneron Pharmaceuticals And 2 Other Stocks Insiders Are Selling
Via Benzinga
Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split
Via The Motley Fool
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
3 No-Brainer Stocks to Buy in July
Via The Motley Fool
3 Pharma Stocks Already Ushering in the Next Biotech Boom
Via InvestorPlace
The 3 Best Biotech Stocks to Buy in July 2024
Via InvestorPlace
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
Via Investor's Business Daily
7 High Priced Stocks That Would Benefit From a Stock Split
Via InvestorPlace
Europe Approves Sanofi/Regeneron's Dupixent for 'Smoker's Lungs' A Month After US FDA Asks For Data
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.